Trial Profile
A Prospective, Observational study to evaluate the efficacy and safety of Sofosbuvir plus Ribavirin in Korean patients with genotype 2 Hepatitis C Virus Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2018
Price :
$35
*
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 15 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018